Sponsored Content

This article is sponsored by AstraZeneca and Merck.

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) cancer survivor Louise (left) and her oncologist, Dr. Ruemu Birhiray (right), built a lasting relationship as they navigated Louise’s diagnosis and relapse. This article is sponsored by MorphoSys and Incyte.

Sponsored by Incyte

This article is sponsored by Aadi Bioscience, Inc.

City of Hope sets the bar for treating people, not just diseases.

Care partners need help, too! That’s why this informational booklet was created. It’s full of practical advice from people who have been in your shoes, caring for someone with non-small cell lung cancer.

Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.

Cindy Cherry, MSN, AGNP-C, and cancer patient Dorothy T. share their experiences with cancer and how they approach chemotherapy treatment.

Learn from survivors! Find out more about care communities, biomarker testing, and how to make the most of every appointment.

Cindy Cherry, MSN, AGNP-C, is an oncology nurse practitioner in Greenville, North Carolina. She treats patients with all types of cancers, including extensive-stage small cell lung cancer (ES-SCLC).

Learn more about the protection of bone marrow and how it may help lower the risk of bone marrow suppression for certain people with small cell lung cancer.

In this episode of the “Cure Talks Cancer” Podcast, Dr. Spira a medical oncologist of the Virginia Cancer Specialists’ (VCS) discusses why KRASG12C is a prolific problem.

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Treating CLL with CALQUENCE® (acalabrutinib)

There are multiple treatment patients for patients with cholangiocarcinoma, here's what you need to know about them.

A clinical research coordinator discusses how patients with cholangiocarcinoma can get involved in clinical trials, such as the phase 3 PROOF trial, as well as what they should know once they are enrolled.

CLL patient shares his experience with the disease and the importance of aiming to live his life to the fullest despite his diagnosis.

Researchers hope the new PROOF trial will show that infigratinib, a targeted drug, will expand options in treating advanced cholangiocarcinoma. Patients are enrolling now.

Patient Rod Gilmore shares his experience with multiple myeloma and the importance of creating a strategy to manage the disease.

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.

An expert on clinical and translational research in gastrointestinal malignancies discusses the promising future of targeted therapy in cholangiocarcinoma treatment.

Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects. Luckily, doctors have a variety of ways to relieve or prevent these discomforts. At the same time, scientists are working to develop new treatments that may be both efficacious and easier for patients to tolerate.

Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities.

AstraZeneca highlights important facts about metastatic breast cancer.